Revisiting the Significance of Prominent C Cells in the Thyroid
C cell hyperplasia is considered a precursor lesion for hereditary forms of medullary thyroid carcinoma. It has therefore been suggested as a morphological marker to distinguish hereditary from sporadic medullary thyroid carcinoma and to triage genetic testing in resource poor settings. However, numerous definitions for C cell hyperplasia have been suggested, and there is surprisingly little data regarding the number of C cells present in thyroid glands removed for conditions other than medullary carcinoma. We therefore sought to investigate the specificity of different criteria for C cell hyperplasia. We examined the number of C cells and solid cell nests (ultimobranchial body remnants) present in 118 completion thyroidectomy specimens from patients without medullary carcinoma and with no risk factors for MEN2. Morphological review was performed on all H&E-stained slides, and immunohistochemistry for calcitonin was performed on one block from each case. Solid cell nests were found in 4 (3.3%) of thyroids. Increased numbers of C cells sufficient to fulfil criteria for C cell hyperplasia were found in 5 (4.2%) to 36 (30.5%) cases depending on the criteria used. We conclude that large numbers of C cells are commonly found in thyroids not associated with medullary carcinoma. Therefore, regardless of which criteria are used, the presence of C cell hyperplasia is not a specific marker for hereditary medullary thyroid carcinoma.
KeywordsMedullary thyroid carcinoma C cell hyperplasia MEN2
Compliance with Ethical Standards
This study was approved by the local institutional ethics committee.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Chan JKC (2007) Tumours of the thyroid and parathyroid glands. In: Fletcher CDM (ed) Diagnostic histopathology of tumors, 3rd edn. Churchill Livingstone Elsevier, New York, pp.1223–1232.Google Scholar
- 5.Gimm O, Morrison CD, Suster S et al (2004) Multiple endocrine neoplasia type 2. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon, pp.211–217.Google Scholar
- 6.Reagh J, Bullock M, Andrici J, Turchini J, Sioson L, Clarkson A, Watson N, Sheen A, Lim G, Delbridge L, Sidhu S, Sywak M, Aniss A, Shepherd P, Ng D, Oei P, Field M, Learoyd D, Robinson BG, Clifton-Bligh RJ, Gill AJ (2017) NRASQ61R mutation-specific immunohistochemistry also identifies the HRASQ61R mutation in medullary thyroid cancer and may have a role in triaging genetic testing for MEN2. Am J Surg Pathol, 41:75–81.CrossRefGoogle Scholar
- 11.Ekblom M et al (1987) Familial and sporadic medullary thyroid carcinoma: clinical and immunohistochemical findings. Quarterly Journal of Medicine 247:899–910.Google Scholar
- 13.LiVolsi V, DeLellis R, Komminoth P et al (2017) Multiple endocrine neoplasia type 2. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds) WHO classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon, pp.248–250.Google Scholar